StockData
Fractyl Health, Inc. logo

Fractyl Health, Inc. (GUTS) company profile

GUTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$0.97−0.03 (-2.66%)

Close on Nov 17, 2026Market cap $153.67MP/E –Yield –

About Fractyl Health

Surgical & Medical Instruments & Apparatus, SIC 3841

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company's lead product candidate is Revita, an outpatient procedural medical device designed to remodel the duodenal mucosal lining via duodenal mucosal resurfacing. In addition, Fractyl is advancing its Rejuva gene therapy platform, which includes lead candidate RJVA-001, targeting metabolic pathways to provide sustained disease-modifying benefits for patients.

The company operates primarily in the United States, conducting research, development, and clinical evaluation across domestic and international clinical sites. Its facilities include office and laboratory space leased in Massachusetts, supported by in-house and contract manufacturing capabilities. Fractyl Health maintains its principal executive offices in Burlington, Massachusetts.

Summary of the business section of Fractyl Health's latest annual report, written by StockData.

Company profile

Company

Legal name
Fractyl Health, Inc.
Founded
2010
Headquarters
Burlington, MA
Address
3 Van De Graaff Drive, Suite 200 01803
Phone
(781) 902-8800
Employees
100, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
GUTS
Exchange
Nasdaq
IPO date
Feb 2, 2024
Shares outstanding
159M, Aug 4, 2026
Public float
$49.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-12 reverse, Oct 5, 2026
SEC CIK
1572616
CUSIP
35168W202
ISIN
US35168W2026
FIGI
BBG002Y7NH72
Share class FIGI
BBG002Y7NH81
EIN
27-3553477

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Harith RajagopalanChief Executive Officer, Director1,143,537
Weber Lara SmithChief Financial Officer20,000
Jay David CaplanPresident, Chief Product Off.631,160
Sarah ToomeyGeneral Counsel–
Timothy KiefferChief Scientific Officer–
Lisa DavidsonChief Financial Officer7,525
Michael J. WartellDirector–
William BradleyDirector149,138
Ajay RoyanDirector5,201,202
Christopher Charles ThompsonDirector–
Marc EliaDirector–
Clive MeanwellDirector277,890
Ian SheffieldDirector35,000
Kelly Ann BarnesDirector31,000
Samuel ConawayDirector0
Amy W. SchulmanDirector8,550

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 2, 2024
Offer price
$15.00
Securities offered
7,333,333
Gross proceeds
$110.00M
Exchange
Nasdaq
First trading day
Feb 2, 2024
First-day close
$12.85-14.3%
Lock-up ends (est.)
Jul 31, 2024

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we have 100 full-time employees, 73 of whom are dedicated to research and development, and 14 of whom hold doctorate degrees (i.e., Ph.D., Pharm.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 11, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 17, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 2, 2024IPOInitial public offering priced (424B4 prospectus)
Jan 29, 2024ListingRegistration of securities on an exchange (Form 8-A)
Mar 19, 2020Name changeName changed from Fractyl Laboratories Inc. to Fractyl Health, Inc.

See a number that looks wrong?